Global Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Global glp-1 agonists weight loss drugs market, 2018-2030 (US$M)
Related Markets
Global glp-1 agonists weight loss drugs market highlights
- The global glp-1 agonists weight loss drugs market generated a revenue of USD 13,843.5 million in 2024 and is expected to reach USD 48,849.3 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 18.5% by 2030.
- In terms of segment, semaglutide (wegovy) accounted for a revenue of USD 12,615.6 million in 2024.
- Tirzepatide (Zepbound) is the most lucrative drug segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Global data book summary
| Market revenue in 2024 | USD 13,843.5 million |
| Market revenue in 2030 | USD 48,849.3 million |
| Growth rate | 18.5% (CAGR from 2025 to 2030) |
| Largest segment | Semaglutide (wegovy) |
| Fastest growing segment | Tirzepatide (Zepbound) |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Wegovy), Liraglutide (Saxenda), Tirzepatide (Zepbound), Other Drugs |
Other key industry trends
- In terms of revenue, the North America accounted for 75.5% of the global glp-1 agonists weight loss drugs market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, India is the fastest growing regional market and is projected to reach USD 352.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Agonists Weight Loss Drugs Market Scope
GLP-1 Agonists Weight Loss Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Company | View profile | - | - | - |
| Structure Therapeutics | View profile | 101-250 | South San Francisco, California, United States, North America | https://structuretx.com/ |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | https://www.vikingtherapeutics.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Global glp-1 agonists weight loss drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 agonists weight loss drugs market will help companies and investors design strategic landscapes.
Semaglutide (wegovy) was the largest segment with a revenue share of 91.13% in 2024. Horizon Databook has segmented the Global glp-1 agonists weight loss drugs market based on semaglutide (wegovy), liraglutide (saxenda), tirzepatide (zepbound), other drugs covering the revenue growth of each sub-segment from 2018 to 2030.
- Global GLP-1 Agonists Weight Loss Drugs Drug Outlook (Revenue, USD Million, 2018-2030)
- Semaglutide (Wegovy)
- Tirzepatide (Zepbound)
- Liraglutide (Saxenda)
- Other Drugs
- Global GLP-1 Agonists Weight Loss Drugs Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Parenteral
- Oral
- Global GLP-1 Agonists Weight Loss Drugs Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Other Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Reasons to subscribe to Global glp-1 agonists weight loss drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global glp-1 agonists weight loss drugs market databook
-
Our clientele includes a mix of glp-1 agonists weight loss drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global glp-1 agonists weight loss drugs market , including forecasts for subscribers. This global databook contains high-level insights into Global glp-1 agonists weight loss drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global glp-1 agonists weight loss drugs market size, by regions, 2018-2030 (US$M)
Top 10 countries: Glp-1 agonists weight loss drugs market size, 2024 (US$M)
Global glp-1 agonists weight loss drugs market share, by drug, 2024 & 2030 (%, US$M)
Glp-1 agonists weight loss drugs market: Opportunity assessment by country
Global glp-1 agonists weight loss drugs market, by region, 2024 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
